NewEdge Wealth LLC Makes New $571,000 Investment in Edwards Lifesciences Corporation $EW

NewEdge Wealth LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 6,703 shares of the medical research company’s stock, valued at approximately $571,000.

A number of other large investors also recently modified their holdings of the company. Washington Trust Advisors Inc. increased its position in shares of Edwards Lifesciences by 5.7% in the 4th quarter. Washington Trust Advisors Inc. now owns 138,005 shares of the medical research company’s stock valued at $11,765,000 after purchasing an additional 7,418 shares during the last quarter. Farmers & Merchants Investments Inc. increased its position in shares of Edwards Lifesciences by 1.6% in the 4th quarter. Farmers & Merchants Investments Inc. now owns 125,707 shares of the medical research company’s stock valued at $10,717,000 after purchasing an additional 1,962 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Edwards Lifesciences by 12.0% in the 4th quarter. Crossmark Global Holdings Inc. now owns 37,110 shares of the medical research company’s stock valued at $3,164,000 after purchasing an additional 3,978 shares during the last quarter. Ethic Inc. increased its position in shares of Edwards Lifesciences by 9.9% in the 4th quarter. Ethic Inc. now owns 48,979 shares of the medical research company’s stock valued at $4,175,000 after purchasing an additional 4,403 shares during the last quarter. Finally, Strategic Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $35,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Monday, May 4th. The shares were sold at an average price of $83.98, for a total transaction of $85,575.62. Following the sale, the vice president directly owned 33,682 shares in the company, valued at $2,828,614.36. This trade represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 88,096 shares of company stock worth $7,288,799 in the last ninety days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $81.34 on Friday. The company’s fifty day moving average price is $81.50 and its 200 day moving average price is $82.86. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market capitalization of $46.84 billion, a P/E ratio of 43.27, a P/E/G ratio of 2.04 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period last year, the business earned $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. Barclays reissued an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. UBS Group reissued a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Finally, Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research report on Wednesday, April 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $95.65.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.